2021
How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome
Sethi TK, Montanari F, Foss F, Reddy N. How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome. British Journal Of Haematology 2021, 195: 352-364. PMID: 33987825, DOI: 10.1111/bjh.17458.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAdrenal Cortex HormonesAgedAntibodies, MonoclonalAntineoplastic AgentsBexaroteneBiomarkers, TumorClinical Trials as TopicCombined Modality TherapyDelayed DiagnosisDiagnosis, DifferentialElectronsHematopoietic Stem Cell TransplantationHistone Deacetylase InhibitorsHumansInterferon-alphaMaleMycosis FungoidesNeoplasm StagingNeoplastic Stem CellsPhotopheresisPrognosisPUVA TherapyRetinoidsSezary SyndromeSignal TransductionSkin NeoplasmsT-Lymphocyte SubsetsConceptsT-cell lymphomaSézary syndromeMultidisciplinary careCutaneous T-cell lymphoma mycosis fungoidesMycosis fungoides/Sézary syndromeCutaneous T-cell lymphomaLines of therapyAdditional treatment optionsNon-Hodgkin lymphomaDuration of useCumulative drug toxicityEarly referralRecurrent diseaseDiagnostic delayPatients' qualityTreatment optionsCommon subtypeTreatable diseaseRare subsetDrug toxicityLymphomaSyndromeDiseasePresent reviewCare
2010
Bortezomib-Induced Tumor Lysis Syndrome in a Patient With HIV-Negative Plasmablastic Lymphoma
Lipstein M, O'Connor O, Montanari F, Paoluzzi L, Bongero D, Bhagat G. Bortezomib-Induced Tumor Lysis Syndrome in a Patient With HIV-Negative Plasmablastic Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2010, 10: e43-e46. PMID: 21856550, DOI: 10.3816/clml.2010.n.074.Peer-Reviewed Original ResearchConceptsTumor lysis syndromePlasmablastic lymphomaLysis syndromeHIV-negative plasmablastic lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaBortezomib-based treatmentHIV-negative patientsDramatic clinical responseB-cell lymphomaWorld Health OrganizationClinical responseImmunocompetent patientsAggressive lymphomaRare lymphomaMultiple myelomaOptimal treatmentLymphomaPatientsHealth OrganizationSyndromeStandard recommendationsTreatmentMyelomaSubtypes